Want to see BTAIQ full AI Analyst Report?
Bioxcel Therapeutics (BTAIQ) Ratios
Bioxcel Therapeutics Ratios
BTAIQ's free cash flow for Q2 2026 was $-6.10M. For the 2026 fiscal year, BTAIQ's free cash flow was increased by $0.00 and operating cash flow was $-6.10M. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 0.83 | 1.68 | 2.65 | 6.17 | 14.21 |
| Quick Ratio | 0.82 | 1.65 | 2.57 | 6.11 | 14.21 |
| Cash Ratio | 0.53 | 1.34 | 2.39 | 5.89 | 13.98 |
| Solvency Ratio | -0.50 | -0.45 | -1.37 | -1.28 | -6.00 |
| Operating Cash Flow Ratio | -1.07 | -3.24 | -5.68 | -4.11 | -4.93 |
| Short-Term Operating Cash Flow Coverage | -2.31 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Current Asset Value | $ -95.69M | $ -94.05M | $ -58.07M | $ 73.79M | $ 219.04M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 2.44 | 2.69 | 1.38 | 0.46 | 0.01 |
| Debt-to-Equity Ratio | -1.15 | -1.11 | -1.79 | 1.23 | 0.01 |
| Debt-to-Capital Ratio | 7.72 | 10.46 | 2.26 | 0.55 | 0.01 |
| Long-Term Debt-to-Capital Ratio | -7.84 | 10.90 | 2.28 | 0.55 | 0.00 |
| Financial Leverage Ratio | -0.47 | -0.41 | -1.30 | 2.68 | 1.08 |
| Debt Service Coverage Ratio | -1.26 | -2.92 | -12.42 | -19.14 | -2665.85 |
| Interest Coverage Ratio | -2.96 | -4.44 | -12.90 | -19.44 | -2647.38 |
| Debt to Market Cap | 5.61 | 6.76 | 1.17 | 0.15 | 0.00 |
| Interest Debt Per Share | 10.37 | 46.58 | 63.00 | 58.47 | 0.87 |
| Net Debt to EBITDA | -1.54 | -1.66 | -0.22 | 0.63 | 2.16 |
| Profitability Margins | |||||
| Gross Profit Margin | 74.45% | 5.43% | 8.70% | 94.67% | 0.00% |
| EBIT Margin | -8241.90% | -1962.49% | -12010.07% | -42011.73% | 0.00% |
| EBITDA Margin | -8195.17% | -1948.85% | -11987.03% | -41924.53% | 0.00% |
| Operating Profit Margin | -7829.75% | -2967.56% | -12447.97% | -42572.00% | 0.00% |
| Pretax Profit Margin | -10887.38% | -2630.14% | -12974.86% | -44201.87% | 0.00% |
| Net Profit Margin | -10887.38% | -2630.14% | -12974.86% | -44201.87% | 0.00% |
| Continuous Operations Profit Margin | -10887.38% | -2630.14% | -12974.86% | -44201.87% | 0.00% |
| Net Income Per EBT | 100.00% | 100.00% | 100.00% | 100.00% | 99.66% |
| EBT Per EBIT | 139.05% | 88.63% | 104.23% | 103.83% | 101.32% |
| Return on Assets (ROA) | -155.62% | -155.46% | -242.94% | -80.52% | -44.66% |
| Return on Equity (ROE) | 73.22% | 64.02% | 316.86% | -215.90% | -48.24% |
| Return on Capital Employed (ROCE) | 557.90% | -417.54% | -369.94% | -92.30% | -47.54% |
| Return on Invested Capital (ROIC) | -314.44% | -408.06% | -367.20% | -92.13% | -47.31% |
| Return on Tangible Assets | -155.62% | -155.46% | -242.94% | -80.52% | -44.66% |
| Earnings Yield | -357.84% | -393.15% | -208.37% | -27.55% | -19.94% |
| Efficiency Ratios | |||||
| Receivables Turnover | 2.76 | 17.30 | 19.44 | 1.51 | 0.00 |
| Payables Turnover | 0.01 | 0.13 | 0.09 | 0.00 | 0.06 |
| Inventory Turnover | 0.23 | 3.16 | 0.63 | 0.01 | 0.00 |
| Fixed Asset Turnover | 2.78 | 2.64 | 0.94 | 0.18 | 0.00 |
| Asset Turnover | 0.01 | 0.06 | 0.02 | 0.00 | 0.00 |
| Working Capital Turnover Ratio | 0.22 | 0.08 | 0.01 | 0.00 | 0.00 |
| Cash Conversion Cycle | -30979.33 | -2586.70 | -3359.79 | -150193.36 | -5749.06 |
| Days of Sales Outstanding | 132.47 | 21.10 | 18.78 | 241.39 | 0.00 |
| Days of Inventory Outstanding | 1606.89 | 115.65 | 576.76 | 36226.25 | 0.00 |
| Days of Payables Outstanding | 32718.69 | 2723.45 | 3955.33 | 186661.00 | 5749.06 |
| Operating Cycle | 1739.36 | 136.75 | 595.54 | 36467.64 | 0.00 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -4.72 | -28.41 | -85.14 | -77.30 | -49.84 |
| Free Cash Flow Per Share | -4.72 | -28.41 | -85.15 | -77.38 | -50.11 |
| Dividend Paid and CapEx Coverage Ratio | 0.00 | 0.00 | -7750.30 | -973.68 | -184.61 |
| Capital Expenditure Coverage Ratio | 0.00 | 0.00 | -7750.30 | -973.68 | -184.61 |
| Operating Cash Flow Coverage Ratio | -0.53 | -0.70 | -1.53 | -1.44 | -58.76 |
| Operating Cash Flow to Sales Ratio | -89.74 | -31.79 | -112.32 | -360.91 | 0.00 |
| Free Cash Flow Yield | -294.97% | -475.13% | -180.41% | -22.51% | -15.41% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -0.28 | -0.25 | -0.48 | -3.63 | -5.01 |
| Price-to-Sales (P/S) Ratio | 30.42 | 6.69 | 62.27 | 1604.70 | 0.00 |
| Price-to-Book (P/B) Ratio | -0.20 | -0.16 | -1.52 | 7.84 | 2.42 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -0.34 | -0.21 | -0.55 | -4.44 | -6.49 |
| Price-to-Operating Cash Flow Ratio | -0.34 | -0.21 | -0.55 | -4.45 | -6.53 |
| Price-to-Earnings Growth (PEG) Ratio | 0.00 | 0.00 | -0.12 | -0.08 | -0.72 |
| Enterprise Value Multiple | -1.92 | -2.00 | -0.74 | -3.19 | -2.85 |
| Enterprise Value | 100.78M | 88.25M | 122.09M | 502.19M | 304.59M |
| EV to EBITDA | -1.92 | -2.00 | -0.74 | -3.19 | -2.85 |
| EV to Sales | 156.97 | 38.95 | 88.47 | 1339.18 | 0.00 |
| EV to Free Cash Flow | -1.75 | -1.23 | -0.79 | -3.71 | -3.69 |
| EV to Operating Cash Flow | -1.75 | -1.23 | -0.79 | -3.71 | -3.71 |
| Tangible Book Value Per Share | -7.82 | -36.73 | -31.04 | 43.85 | 134.48 |
| Shareholders’ Equity Per Share | -7.82 | -36.73 | -31.04 | 43.85 | 134.48 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Revenue Per Share | 0.05 | 0.89 | 0.76 | 0.21 | 0.00 |
| Net Income Per Share | -5.73 | -23.51 | -98.35 | -94.67 | -64.87 |
| Tax Burden | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
| Interest Burden | 1.32 | 1.34 | 1.08 | 1.05 | 1.00 |
| Research & Development to Revenue | 47.12 | 13.43 | 61.11 | 243.30 | 0.00 |
| SG&A to Revenue | 31.92 | 15.22 | 46.02 | 148.68 | 0.00 |
| Stock-Based Compensation to Revenue | 4.31 | 2.72 | 13.49 | 46.23 | 0.00 |
| Income Quality | 0.82 | 1.21 | 0.87 | 0.82 | 0.77 |
Currency in USD
